Life sciences — US PTAB Patent Cases
3 decisions indexed
Page 1 of 1 · 3 total
QIAGEN Sciences, LLC v.Tecan Group AG
The Director denied QIAGEN's request for review of the institution decision in IPR2025-00027, leaving the institution standing. No patentability arguments were revisited.
QIAGEN Sciences, LLC v.Tecan Group AG
PTAB issued Director Review requests for IPR2025-00028 and IPR2025-00029, limiting responses to five pages and prohibiting new evidence. QIAGEN and Tecan must file brief replies within five business days.
Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.
Nanostring Technologies challenges U.S. Patent No. 11,542,554 in a PTAB Petition, arguing that numerous claims are obvious over combinations of prior art references like Zhuang, Cai, and Shen. The petitioner asserts the core technology for 3D positional information in nucleic acid imaging was already well-known in biological imaging.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.